Vir Biotechnology, Inc. — Form 10-Q
Filed August 5, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 28/100
What the filing says
On June 24, 2026, Vir Biotechnology executed a Second Amendment to its License Agreement with Sanofi (via Amunix Pharmaceuticals). The amendment expands the scope of the original July 31, 2024 agreement by adding additional Licensed Know-How (Exhibit A) and Licensed Amunix Sub-Platform Patents (Exhibit B) to the existing agreement schedules. Specific dollar amounts, payment terms, and detailed IP descriptions are redacted as confidential. No financial impact, milestones, or royalty changes are disclosed in this filing excerpt.
Why this rating
Routine amendment to existing pharma licensing deal. No financial terms, valuation, or commercial impact disclosed. Procedural IP scope expansion typical in biotech partnerships. Immaterial to $689M company.
See more from August 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.